Moreover, TLR agonists like Diprovocim (TLR1/2) (125), 1V270 (TLR7) (22) and SD-101 (TLR9) (126) have shown synergistic effects with immune checkpoint inhibitors thus enhancing the tumor immunogenicity (Table 1). The gene discussed is TLR7; the disease is neoplasm.